The in vitro addition of PD-1 with or without CTLA-4 inhibitors with blinatumomab to BCP-ALL blasts and peripheral blood mononuclear cells led to increased T cell proliferation and enhanced blinatumomab-mediated cytotoxicity [79]. This evidence concerns the gene CTLA4 and acute lymphoblastic leukemia.